IntelGenx Technologies Corp. (IGXT)
| Market Cap | 41.92M |
| Revenue (ttm) | 1.27M |
| Net Income (ttm) | -10.80M |
| Shares Out | 174.65M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 617,355 |
| Open | 0.207 |
| Previous Close | 0.238 |
| Day's Range | 0.207 - 0.270 |
| 52-Week Range | 0.110 - 0.370 |
| Beta | 2.49 |
| Analysts | Buy |
| Price Target | 0.81 (+237.5%) |
| Earnings Date | Mar 22, 2023 |
About IGXT
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients und... [Read more]
Financial Performance
In 2021, IGXT's revenue was $1.54 million, a decrease of -0.58% compared to the previous year's $1.54 million. Losses were -$9.31 million, 32.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IGXT stock is "Buy." The 12-month stock price forecast is $0.81, which is an increase of 237.50% from the latest price.
News
CORRECTION – IntelGenx to Participate in the 35th Annual Roth Conference
SAINT LAURENT, Quebec, March 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT), please note that the time of...
IntelGenx to Participate in the 35th Annual Roth Conference
SAINT LAURENT, Quebec, March 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, will be participating in...
IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent
SAINT LAURENT, Quebec, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that the United States...
IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson's Disease
SAINT-LAURENT, Quebec, Feb. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced a research collaborati...
IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries
SAINT LAURENT, Quebec, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, announced today that it has entered in...
IntelGenx Receives FDA PDUFA Date for RIZAFILM®
SAINT LAURENT, Quebec, Nov. 22, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the U.S. Food and...
IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor
SAINT LAURENT, Quebec, Nov. 10, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that its third quarter 202...
IntelGenx Enters into Feasibility & Development Agreement For CBD-Infused VetaFilm™
SAINT LAURENT, Quebec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that it has entered in...
IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its t...
IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action
SAINT LAURENT, Quebec, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced it has filed a new pro...
IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
SAINT LAURENT, Quebec, Oct. 25, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its previously undisclosed development candidate, Bu...
IntelGenx's Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic partner,...
IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures
SAINT LAURENT, Quebec, July 05, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces that, as previously disclosed on June 1, 2022 and ...
IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, May 05, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fi...
IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
SAINT LAURENT, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that management will pres...
IntelGenx Reports Fourth Quarter and Full-Year 2021 Financial Results
SAINT LAURENT, Quebec, March 24, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-m...
IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, March 17, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its ...
First Patient Dosed in IntelGenx's Resumed ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in pharmaceutical films, today announced that patient dosing ha...
IntelGenx Initiates Arbitration Proceeding Against Tilray® Related to an Alleged Breach of Worldwide Cannabis-Infused VersaFilm® Agreement
SAINT LAURENT, Quebec, Dec. 08, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has initiated an arbitration proceeding against T...
IntelGenx Reports Third Quarter 2021 Financial Results
SAINT LAURENT, Quebec, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended...
IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its t...
IntelGenx Receives Final Approval to Graduate to Toronto Stock Exchange
SAINT LAURENT, Quebec, Oct. 05, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or ”the “Company”) announces that it has received final approval to graduat...
IntelGenx and Aquestive Therapeutics Partner with Leading Men's Health Company to Market Tadalafil Oral Films in the U.S.
SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral...
IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to Toronto Stock Exchange
SAINT LAURENT, Quebec, Sept. 15, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx...
IntelGenx Announces Market Launch of RIZAPORT® in Spain
SAINT LAURENT, Quebec, Sept. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercia...